This study aimed to evaluate the role of microbiota and probiotics in Egyptian patients with ulcerative colitis.

Inflammatory bowel disease (IBD) is a group of chronic diseases that significantly affects patients' quality of life and is mainly represented by Crohn's disease (CD) and ulcerative colitis (UC).

The microbiome is a key contributor to various fundamental aspects of human health, including host metabolism, infection, and the immune response.

Changes in microbiome composition have been linked to complex multifactorial diseases, e.g., type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver syndrome, as well as inflammatory bowel disease (IBD).

Inclusion Criteria:

• Patients more than 18 years.
• Patients with ulcerative colitis in remission as assessed by the clinical activity index (CAI) ≤ 4, endoscopic index (EI) ≤ 4, and no signs of acute inflammation on histological examination.

Exclusion Criteria:

• Active ulcerative colitis.
• Cardiac, hepatic, or renal disease.
• Pregnancy.
• History of major colonic surgery.
• Patients with any malignancy.
• Previously taking other probiotics.
• Use of steroids within the last 4 weeks before study entry.
• Use of antibiotics within the last 2 weeks before study entry

This study is a prospective study that will be carried in Tanta University Hospital, Tropical Medicine and Infectious Diseases Department.

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

After the end of study for one year.

The data will be available upon a reasonable request from the corresponding author.